News

Kyowa Kirin 1H Net Y16.32B Vs Net Y37.78B
Kyowa Kirin Co. Ltd. (4151.TO) Tokyo Half-Year Ended June 30 GROUP 2025 2024 Revenue Y230.65 bln Y232.97 bln Pretax Profit Y21.98 bln Y46.52 bln Net Profit Y16.32 bln Y37.78 bln Per share Earnings Y31 ...
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with ...
Beverage Industry2d
Consumers turn to beverages for immune support
Consumers are increasingly prioritizing long-term health and focusing on prevention over cure with beverages acting as a ...
Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029
Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...
GSK wins EU approval for drug combos containing blood cancer drug Blenrep
GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...